# MCL 500.3406e

IRI: <https://ontology.bommaritollc.com/id/01a0d565-dcbd-76bf-9e20-e639d3e5880e>

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [mcl-object mcl-500-3406e](https://ontology.bommaritollc.com/id/01a0d565-dcbe-73fe-b30d-3ef2d32587ab)
- `prov:wasDerivedFrom`: [evidence from https://www.legislature.mi.gov/Laws/MCL?objectName=mcl-500-3406e](https://ontology.bommaritollc.com/id/01a0d565-dcbd-76bf-9e20-e63825e13e49)
- `schema:isPartOf`: [1956 PA 218](https://ontology.bommaritollc.com/id/01a0d565-2054-7061-9841-4204f29f7809)
- `schema:legislationIdentifier`: MCL 500.3406e
- `schema:legislationJurisdiction`: [Michigan](https://ontology.bommaritollc.com/id/01a0ca47-57ff-7219-9e2f-cdc1b39bd0fa)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [MCL section](https://ontology.bommaritollc.com/vocab/leg/mclSection)
- `schema:name`: Coverage for drug used in antineoplastic therapy and cost of its administration; conditions.
- `schema:url`: [https://www.legislature.mi.gov/Laws/MCL?objectName=mcl-500-3406e](https://www.legislature.mi.gov/Laws/MCL?objectName=mcl-500-3406e)
- `skos:prefLabel`: MCL 500.3406e

## Pointing here

- `eli:amends`:
  - [2016 PA 276](https://ontology.bommaritollc.com/id/01a0d565-3ae5-7090-be7a-4cfa716d3761)
- `eli:changes`:
  - [1989 PA 59](https://ontology.bommaritollc.com/id/01a0d565-3b53-75e5-9a5b-5a3d58d22fb8)
- `schema:legislationChanges`:
  - [SB 738 (2023-2024)](https://ontology.bommaritollc.com/id/01a0d569-4986-7589-a026-90529b9b1e2f)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0d565-dcbd-76bf-9e20-e639d3e5880e.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0d565-dcbd-76bf-9e20-e639d3e5880e.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0d565-dcbd-76bf-9e20-e639d3e5880e.nt), [HTML](https://ontology.bommaritollc.com/id/01a0d565-dcbd-76bf-9e20-e639d3e5880e)
Release 0.1.0-rc11, graph hash bb101db30ae52707df7631dcab4c59352e4fa3631e6fbf2938c380193642bb51.